

Summary of Product Characteristics

1. Name of the Medicinal Product

Sinuclear® Syrup
Syrup to be taken orally

2. Qualitative and Quantitative Composition

1 ml syrup contains: 417 mg extract (1:38.5) from 0.011 g of a mixture of gentian root, verbena herb, common sorrel herb, elder flower, primula flower with calyx (1:3:3:3:3); 1. extracting agent: ethanol 59% (V/V), 2. - 4. extracting agent: purified water.

This medicinal product contains 8% (V/V) alcohol.

This medicine contains 448 mg of alcohol (ethanol) in 7.0 ml which is equivalent to 64 mg/ml (8 % V/V). The amount in 7.0 ml of this medicine is equivalent to 12 ml beer or 5 ml wine. The small amount of alcohol in this medicine will not have any noticeable effects.

Excipients with known effect:

Maltitol solution 78.8 g

For the full list of excipients, see section 6.1.

3. Pharmaceutical Form

Syrup to be taken orally

4. Clinical Particulars

4.1 Therapeutic Indications

Provides relief of symptoms in the nose and its sinuses in connection with common cold, in adults and children older than 12 years.

4.2 Posology and Method of Administration

Posology

Unless otherwise prescribed, Sinuclear® Syrup is taken three times a day in a dose that is appropriate to the age of the patient according to the table below using the enclosed measuring cup.

Age	Single dose	Total daily dose
Adults and children from 12 years of age	7.0 ml = 8.4 g	21.0 ml = 25.2 g (3 x 7.0 ml)

There is insufficient data available for specific dosage recommendations in the case of impaired kidney/liver function.

Method of Administration

Sinuclear® Syrup is taken 3 times a day (in the morning, at lunchtime and in the evening) undiluted or in a little water. If necessary, rinse down with liquid (no alcohol), i.e. preferably a glass of drinking water. Sinuclear® Syrup can be taken together with food, with drinks or independently of meals. The best time for patients with a sensitive stomach to take Sinuclear® Syrup is after meals. Shake before use!

Unless otherwise prescribed, the length of administration is as follows: 7-14 days. Please also note the information under 4.4. "Special Warnings and Precautions for Use".

4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

4.4 Special Warnings and Precautions for Use

Particular care is required when this medicine is taken by patients with known inflammation of the stomach and those with a sensitive stomach. Sinuclear® Syrup is best taken after meals and with a glass of water.

In the case of symptoms that last longer than 7-14 days or symptoms which worsen or recur periodically and/or in the event that the patient has a high temperature, nosebleeds, severe pain, purulent nasal secretions, visual disturbances, asymmetry of the midface or eyes, or facial numbness, a differential diagnosis and medical treatment are required.

This medicinal product contains 8% (V/V) alcohol.

Patients with rare hereditary fructose intolerance should not take Sinuclear® Syrup.

7.0 ml of Sinuclear® Syrup contain 5.5 g of maltitol solution, which corresponds to approx. 0.35 bread units (BU). This must be taken into account in patients with diabetes mellitus. The caloric value of maltitol solution in each 7 ml dose is 12.65 kcal. Maltitol may have a mild laxative effect.

Children

The medicinal product is not indicated for children under the age of 12 years.

4.5 Interaction with other Medicinal Products and other Forms of Interaction

There are currently no known interactions with other medicinal products.

4.6 Fertility, Pregnancy and Lactation

Pregnancy and Lactation

There are no data available on the use of Sinuclear® Syrup during pregnancy. A retrospective analysis that was conducted for Sinuclear® drops and Sinuclear® Powder with 762 pregnant women showed no evidence of teratogenic potential or embryotoxicity. Animal studies have not shown any evidence of direct or indirect adverse health effects with regard to reproductive toxicity (see section 5.3).

Sinuclear® Syrup may be used during pregnancy if this is considered to be clinically necessary.

It is not known whether the active ingredients in Sinuclear® Syrup or their metabolites pass into the breast milk. A risk to the breast-fed infant cannot be ruled out. Sinuclear® Syrup should be administered during the lactation period only according to strict indication criteria.

Fertility

There are no data available on the influence of Sinuclear® Syrup on fertility. No effects on fertility have been observed in animal studies with Sinuclear® drops and Sinuclear® (see section 5.3).

4.7 Effects on Ability to Drive and Use Machines

No special precautions are required.

4.8 Undesirable Effects

Like all medicines, Sinuclear® Syrup can cause side effects.

The following categories are used as a basis for the frequency data on side effects:

Very common ($\geq 1/10$)

Common ($\geq 1/100$ to $< 1/10$)

Uncommon ($\geq 1/1,000$ to $< 1/100$)

Rare ($\geq 1/10,000$, $< 1/1,000$)

Very rare ($< 1/10,000$)

Not known (the frequency cannot be estimated on the basis of the available data)

Uncommonly, gastrointestinal complaints (including stomach pain, nausea) may occur.

Uncommonly, hypersensitivity reactions of the skin (rash, redness, itching) may occur.

Severe allergic reactions (angio-oedema, respiratory distress, facial swelling) may also occur. The frequency is not known.

The patient is advised in the package leaflet that at the first signs of a hypersensitivity reaction, Sinuclear® Syrup must not be taken again.

Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: <https://sideeffects.health.gov.il>

Or In addition, suspected adverse events can be reported directly to Dr. Samuelov's drug safety department at: drugsafety@drsamuelov.co.il

4.9 Overdose

There have been no reports so far of intoxications with Sinuclear® Syrup.
It is possible that the side effects listed above occur more frequently in the case of an overdose.

Therapy of intoxications:

If symptoms of poisoning or overdose occur, symptomatic therapy is required.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic Properties

Pharmacotherapeutic Group: Herbal medicinal product for the treatment of inflammation of the paranasal sinuses.

ATC code: R05X

5.2 Pharmacokinetic Properties

Studies on pharmacokinetics or bioavailability have not been carried out, as not all of the active substances are known in detail.

5.3 Preclinical Safety Data

The pre-clinical data on Sinuclear® Syrup are incomplete. Based on many years of medical experience, there is sufficient evidence of safe use in humans.

Chronic Toxicity

In repeated-dose toxicity studies, a Sinuclear® dry extract was administered orally to dogs (39 weeks) and rats (26 weeks). The No Observed Adverse Effect Level (NOAEL) in both the dog and rat was 320 mg/kg of body weight, which is equivalent to 178 times (dog) and 52 times (rat) the recommended therapeutic dose of Sinuclear® Syrup when converted to the body surface area.

Mutagenicity

In vitro in the Salmonella typhimurium reverse mutation assay (AMES) and the mouse lymphoma test, as well as in a series of *in vivo* studies in mice and rats (UDS test, micronucleus test), no mutagenic potential was detected for different Sinuclear® formulations (Sinuclear® coated tablets, Sinuclear® drops, Sinuclear® native dry extract).

Reproductive and Developmental Toxicity

No effects on fertility, embryo-foetal or peri- and post-natal development and no teratogenic effects have been observed for Sinuclear® drops or Sinuclear® in several species (rat and rabbit). Studies with Sinuclear® dry extract in rabbits on reproductive toxicity have shown that up to the highest investigated dose of 800 mg/kg of body weight, embryo-foetal development was not affected and no teratogenic effects occurred. After conversion to the body surface area, this corresponds to a safety factor of 258 compared to the recommended therapeutic dose of Sinuclear® Syrup.

Carcinogenicity

There are no carcinogenicity studies available involving the long-term administration of Sinuclear®.

Phototoxicity

There are no studies available on phototoxicity.

Safety Pharmacology

Studies on the receptor-binding affinity and neuropharmacological, cardiovascular and respiratory safety of various Sinuclear® formulations (Sinuclear® drops, Sinuclear® dry extract) did not reveal any safety-relevant findings.

6. PHARMACEUTICAL PARTICULARS

6.1 List of Excipients

Liquid maltitol.
Cherry flavouring

6.2 Incompatibilities

None known.

6.3 Shelf Life

The expiry date of the product is indicated on the packaging materials.

The shelf life is 6 months after opening.

6.4 Special Precautions for Storage

Do not store above 30°C.

As with all herbal medicines, Sinuclear® Syrup may develop slight cloudiness or precipitation during prolonged storage. This does not have a negative effect on the quality.

6.5 Nature and Contents of Container

Pack of 100 ml of syrup for oral use.

6.6 Further Information

No special requirements.

7. Manufacturer:

BIONORICA SE
Kerschensteinerstraße 11-15
92318 Neumarkt, Germany
Telephone: +49 (0)9181 / 231-90
Fax: +49 (0)9181 / 231-265

8. ISRAELI MARKETING AUTHORIZATION HOLDER AND IMPORTER:

Dr. Samuelov Importing & Marketing Ltd.
13 Hasadna st, POB 2486
Ra'anana 4365007 Israel
Phone: 09 7483769

9. Marketing Authorisation Number

171-01-34683-00

10. Date of First Authorisation / Renewal of the Authorisation

December 2022

11. Date of Revision of the Text

December 2022

12. Classification for Supply

Over the counter, Available only in pharmacies

Sinuclear Syrup SmPc 1222